TrialThe British journal of dermatology2022

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).

Andrew Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.